Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction
Alberto M. Marra, Roberta D’Assante, Mariarosaria De Luca, Michele Arcopinto, Paola Gargiulo, Valeria Valente, Giulia Crisci, Carmen Rainone, Michele Modestino, Federica Giardino, Stefania Paolillo, Francesco Cacciatore, Lavinia Saldamarco, Dario Bruzzese, Donatella Scarpa, Pasquale Perrone Filardi, Giovanni Esposito, Luigi Saccà, Eduardo Bossone, Andrea Salzano, Antonio Cittadini
Abstract
BACKGROUND: Growing evidence suggests that reduced activity of the growth hormone (GH)/insulin-like growth factor (IGF)-1 axis is common and associated with poor clinical status and outcome in heart failure (HF). In addition, preliminary results of growth hormone deficiency (GHD) correction in HF showed an improvement in quality of life, cardiac structure and function, and cardiovascular performance. OBJECTIVES: The aim of the present double-blind, randomized, placebo-controlled trial was to evaluate the cardiovascular effects of 1 year of GH replacement therapy in a cohort of patients with heart failure and reduced ejection fraction (HFrEF). METHODS: ). Secondary endpoints included hospitalizations, end-systolic left ventricular volumes, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, health-related quality of life score, and muscle strength (handgrip). RESULTS: slope; P < 0.05) also improved, paralleled by an increase in 6-minute walking test distance (P < 0.05) and handgrip strength (P < 0.01). GH improved right ventricular function (ie, TAPSE and TAPSE/pulmonary artery systolic pressure ratio; P < 0.01), leading to an amelioration of clinical status (NYHA functional class; P < 0.05) and health-related quality of life (Minnesota Living With Heart Failure Questionnaire; P < 0.05). A significant decrease of NT-proBNP was also found (P < 0.05). CONCLUSIONS: This randomized, double-blind, placebo-controlled trial demonstrates that GH replacement therapy in HFrEF patients with GHD improves exercise performance, and left ventricular and right ventricular structure and function, leading to an amelioration of clinical status and health-related quality of life. (Treatment of GHD Associated With CHF; NCT03775993).